Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,264 shares of the biopharmaceutical company’s stock after selling 1,149 shares during the quarter. Vontobel Holding Ltd.’s holdings in Alnylam Pharmaceuticals were worth $1,998,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in ALNY. Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock worth $1,792,542,000 after buying an additional 50,366 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after purchasing an additional 201,784 shares in the last quarter. Capital International Investors lifted its position in shares of Alnylam Pharmaceuticals by 1.8% during the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock worth $545,674,000 after purchasing an additional 64,560 shares during the last quarter. Capital Research Global Investors grew its stake in Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after purchasing an additional 214,908 shares in the last quarter. Finally, Bellevue Group AG increased its holdings in Alnylam Pharmaceuticals by 3.7% in the first quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company’s stock valued at $137,238,000 after buying an additional 32,966 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $19,829,070. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Yvonne Greenstreet sold 15,148 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,829,070. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the sale, the director now owns 136 shares in the company, valued at approximately $35,632. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,398 shares of company stock valued at $13,595,460 in the last quarter. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $295.93 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a market cap of $37.43 billion, a P/E ratio of -110.42 and a beta of 0.39. The stock has a fifty day moving average price of $271.82 and a two-hundred day moving average price of $216.59.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same period in the prior year, the business earned ($2.21) EPS. The company’s quarterly revenue was up 107.0% compared to the same quarter last year. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on ALNY. Evercore ISI lifted their target price on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 25th. UBS Group boosted their target price on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a research note on Friday, June 28th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $234.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a research report on Friday, July 12th. Finally, JPMorgan Chase & Co. raised their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Six equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $286.82.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.